All PhRMA articles
-
Business
Drug companies reluctantly accept state price negotiations
As legal challenges fall flat, will industry’s claims of stifled innovation be borne out?
-
Business
Pharmaceuticals roundup 2023
Regulatory and pricing reforms have topped industry agendas in 2023, while weight loss drugs surged and Covid-19 therapies waned
-
Business
Pharmaceuticals roundup 2022
Following the huge success of vaccines and treatments for covid-19, companies are upping their investment in R&D and dealmaking
-
Business
Striving to bolster the antibiotic pipeline before it becomes the next crisis
It’s been almost 10 years since the world was warned of a post-antibiotic apocalypse. Katrina Megget takes a look at the initiatives trying to support antimicrobial R&D
-
Business
Stepping towards diversity in industry
Companies are re-affirming their commitment to inclusivity, even as the US government obstructs education efforts
-
Feature
Deal or no deal?
Clare Sansom highlights recent changes in the landscape of pharma company collaborations and acquisitions
-
News
Big budget boost for US medical research
Cancer, precision medicine and health research receive funding boost in bill derided by some as a giveaway for pharma
-
Business
Unpicking doctor payments
Accepting even small meals from drug industry reps appears to influence doctors’ prescription rates
-
Business
Controversial new trade deal finalised
The Trans-Pacific Partnership could raise the price of medicines, especially in developing nations
-
Business
Trade agreement could limit access to medicines
If approved in its leaked form, the Trans-Pacific Partnership would pose barriers for generic drugs to enter the market and keep drug prices high, warns the Foundation for Aids Research